The pathologic galaxy modulating the genotype and phenotype of inflammatory bowel disease: Comorbidity, contiguity, and genetic and epigenetic factors

Minerva Medica

Volumn 107, Issue 6, 2016, Pages 401-412

  Actis, Giovanni C ^a   Pellicano, Rinaldo ^b  

^a Multidisciplinary Private Practice Office   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Classification; Comorbidity; Etiology; Inflammatory bowel diseases

Indexed keywords

ADALIMUMAB; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CD3 ANTIGEN; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 2; MYCOPHENOLIC ACID; RITUXIMAB; STAT PROTEIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; X LINKED INHIBITOR OF APOPTOSIS;

ADAPTIVE IMMUNITY; ANAPHYLACTOID PURPURA; AORTA ARCH SYNDROME; AUTOINFLAMMATORY DISEASE; BEHCET DISEASE; CHRONIC GRANULOMATOUS DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMON VARIABLE IMMUNODEFICIENCY; COMORBIDITY; COMPLEMENT DISORDER; CROHN DISEASE; DRUG INDUCED DISEASE; EPIGENETICS; EPOXYGENASE GENE; GENE; GENE MUTATION; GENETIC TRAIT; GENOTYPE PHENOTYPE CORRELATION; IMMUNE DEFICIENCY; IMMUNOGLOBULIN A DEFICIENCY; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; REVIEW; SYSTEMIC MASTOCYTOSIS; WEGENER GRANULOMATOSIS; WISKOTT ALDRICH SYNDROME; COMPLICATION; GENETIC EPIGENESIS; GENETICS; GENOTYPE; HUMAN; IMMUNOLOGY; PHENOTYPE;

EPIGENESIS, GENETIC; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; PHENOTYPE;

EID: 84991294527     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Ardesia M, Villanacci V, Fries W. The aged gut in inflammatory bowel diseases. Minerva Gastroenterol Dietol 2015;61:235-47.
2. Actis GC, The changing face of inflammatory bowel disease: etiology, physiopathology, epidemiology. Ann Colorectal Res 2016;4:e32942.
3. Actis GC, Rosina F. Inflammatory bowel disease: an archetype disorder of outer environment sensor systems. World J Gastrointest Pharmacol Ther 2013;4:41-6.
4. Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut 2013;62:1795-805.
5. Uhlig HH, Schwerd T. From genes to mechanisms: the expanding spectrum of monogenic disorders associated to IBD. Inflamm Bowel Dis 2016;22:202-12.
6. Glocker E, Grimbacher B. Inflammatory bowel disease: is it a primary immunodeficiency? Cell Mol Life Sci 2012;69:41-8.
7. Marks DJ, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am J Gastroenterol 2009;104:117-24.
8. Marks DJ. Pathological features of inflammatory bowel disease in CGD are indistinguishable from those observed in Crohn's disease. Gastroenterology 2007;132 (suppl 1):156-7.
9. Lange AJ, Arion WJ, Beaudet AL. Type 1b glycogen storage disease is caused by a defect in the glucose-6-phosphatase system. J Biol Chem 1980;255:8381-4.
10. Visser G, Rake JP, Fernandes J, Labrune P, Leonard JV, Moses S, et al. Neutropenia, neutrophil dysfunction, and IBD in glycogen storage disease type 1b: results of the European Study on Glycogen Storage Disease type1. J Pediatr 2000;137:187-91.
11. Cannon JL, Burckhardt JK. Differential roles for Wiskott-Aldrich syndrome protein in immune synapse formation and IL2 production. J Immunol 2004;173:1658-62.
12. Cannioto Z, Berti I, Martelossi S, Bruno I, Giurici N, Crovella S, et al. IBD and IBD mimicking enterocolitis in children younger than 2 years of age. Eur J Pediatr 2009;168:149-55.
13. Marks DJ, Seymour CR, Sewell GW, Rahman FZ, Smith AM, McCartney SA, et al. IBD in patients with adaptive and C' immunodeficiency disorders. Inflamm Bowel Dis 2000;16:1984-92.
14. Daniels JA, Lederman HM, Maitra A, Montgomery EA. Gastrointestinal tract pathologies in patients with common variable immunodeficiency: clinic-pathologic study and review. Am J Surg Pathol 2007;31:1800-12.
15. Chua I, Standish R, Lear S, Harbord M, Eren E, Raeiszadeh M, et al. Anti-TNF alpha therapy for severe enteropathy in patients with CVID. Clin Exp Immunol 2007;150:306-11.
16. Actis GC, Pellicano R, Rosina F. Inflammatory bowel disease: Traditional knowledge holds the seeds for the future. World J Gastrointest Pharmacol Ther 2015;6:10-6.
17. Yuan Fu X. STAT-3 in immune responses and IBD. Cell Res 2006;16:214-9.
18. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, et al. IBD and mutations affecting the IL10 receptor. N Engl J Med 2009;361:2033-45.
19. Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, Schirmacher P, et al. Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med 2010;207:1617-24.
20. Blaydon DC, Biancheri P, Di WL, Plagnol V, Cabral RM, Brooke MA, et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med 2011;365:1502-8.
21. Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B, et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable IBD. Genet Med 2011;13:255-62.
22. Coelho R, Peixoto A, Amil-Dias J, Trindade E, Campos M, Magina S, et al. Refractory monogenic Crohn's disease due to X-linked inhibitor of apoptosis deficiency. Int J Colorectal Dis 2016;31:1235-6.
23. Fiskerstrand T, Arshad N, Haukanes BI, Tronstad RR, Pham KD, Johansson S, et al. Familial diarrhea syndrome caused by an activating GUCY2C mutation. New Engl J Med 2012;366:1586-95.
24. Bystrom J, Thomson SJ, Johansson J, Edin ML, Zeldin DC, Gilroy DW, et al. Inducible CYP2J2 and its product 11,12 EET promotes bacterial phagocytosis: a role for CYP2J2 deficiency in the pathogenesis of Crohn's disease? PLoS One 2013;8: e75107.
25. Yao Q, Furst DE. Auto-inflammatory diseases: an update of clinical and genetic aspects. Rheumatology 2008;47:946-51.
26. Ancient missense mutations in a new member of the RoRet gene family are likely to cause fam Mediterranean fever. The Internatl FMF consortium. Cell 1997;90:797-807.
27. A candidate gene for familial Med Fever, The French FMF consortium. Nat Genet 1997;17:25-31.
28. Kuloǧlu Z, Kansu A, Ustündaǧ G, Birsin Özçakar Z, Ensari A, Ekim M. An infant with severe refractory CD and homozygous MEFV mutations who dramatically responded to colchicines. Rheumatol Int 2012;32:783-5.
29. Sari S, Egritas O, Dalgic B. The MEFV gene may be a modifier factor of IBD in infancy. Eur J Pediatr 2008;167:391-3.
30. Takahashi T, Tsukuda H, Itoh H, Kimura H, Yoshimoto M, Tsujisaki M. An atypical familial Mediterranean fever patient who developed ulcers in the terminal ileum and recurrent abscess-like lesions in multiple organs. Intern Med 2012;51:2239-44.
31. Bedeir A, Jukic DM, Wang L, Mullady DK, Regueiro M, Krasinskas AM. Systemic mastocytosis mimicking IBD: a case report and discussion of gastrointestinal pathology in systemic mastocytosis. Am J Surg Pathol 2006;30:1478-82.
32. Vincenzi B, Finolezzi E, Fossati C, Verzì A, Santini D, Tonini G, et al. Unusual presentation of Hodgkin disease mimicking IBD. Leuk Lymphoma 2001;42:521-6.
33. Narula N, Vasudev M, Marshall JK. IgG4-related sclerosing disease: a novel mimic of IBD. Dig Dis Sci 2010;55:3047-51.
34. Culver EL, Winearls C, Roberts I, Keshav S. A rare cause of bloody diarrhea. Gut 2012;61:819-20.
35. Kao PC, Vecchio JA, Hyman NH, West AB, Blaszyk H. Idiopathic myointimal hyperplasia of mesenteric veins: a rare mimic of idiopathic inflammatory bowel disease. J Clin Gastroenterol 2005;39: 704-8.
36. Suzuki Kurokawa M, Suzuki N. Behçet disease. Clin Exp Med 2004;4:10-20.
37. Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behçet disease: evolution of clinical manifestations. Medicine 2011;90:125-32.
38. Jung ES, Kim SW, Moon CM, Shin DJ, Son NH, Kim ES, et al. Relationship between genetic polymorphisms of triggering receptor expressed on myeloid cells-1 and IBD. In the Korean population. Life Sciences 2011;89:289-94.
39. Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 2009;21:38-46.
40. Ozaslan E. Ileo-colonic findings in Behçet disease. Digestion 2010;82:258-9.
41. Kim ES. A case of intestinal Behçet disease similar to Crohn's colitis. J Korean Med Sci 2007;22:918-22.
42. Grigg EI, Kane S, Katz S. Mimicry and deception in inflammatory bowel disease and intestinal Behçet disease. Gastroenterol Hepatol (NY) 2012;8:103-12.
43. Qian Q, Cornell L, Chandan V, Hartman R, Caples S. Hemorragic colitis as a presenting feature of Wegener granulomatosis. J Gastrointest Liver Dis 2010;19:445-7.
44. Vavricka SR, Dirnhofer S, Degen L. Polyarteritis Nodosa mimicking IBD. Clin Gastroenterol Hepatol 2007;5:A22.
45. Shahedi K, Hanna RM, Melamed O, Wilson J. Wegener's granulomatosis mimicking inflammatory bowel disease and presenting with chronic enteritis. Int Med Case Reports J 2013;6:65-9.
46. Soylemezoglu O, Peru H, Gonen S, Cetinyurek A, Buyan N. HLA-DRB1 alleles and Henoch-Schönlein purpura: susceptibility and disease severity. J Rheumatol 2008;35:1165-8.
47. Cassater D, Gambaro G, Fabris A, Cena C, Calabria S, Capelluto S, et al. Henoch-Schönlein purpura and Crohn's disease in a family. J Nephrol 2006;19:387-90.
48. Rahman FZ, Takhar GK, Roy O, Shepherd A, Bloom SL, McCartney SA. Henoch-Schönlein purpura complicating adalimumab therapy for Crohn's disease. World J Gastroent Pharmacol Ther 2010;1:119-22.
49. Samuel S, Loftus EV Jr, Sandborn WJ. Henoch-Schönlein purpura in an adult mimicking Crohn's disease and pyoderma gangrenosum. Dig Dis Sci 2011;56:2205-6.
50. Kusunoki R, Ishihara S, Sato M, Sumita Y, Mishima Y, Okada M, et al. Rare case of Takayasus arteritis associated with Crohn's disease. Intern Med 2011;50:1581-5.
51. Takahashi N, Tanabe K, Sugamori T, Sato M, Kitamura J, Sato H, et al. Association between Takayasus arteritis and ulcerative colitis: case report and review of serological HLA analysis. Med Sci Monitor 2011;17:CS81-4.
52. Nguyen MC, Kaeser P. Takayasus disease associated with Crohn's: two identical diseases at different sites. Rev Med Suisse 2011;7:1325-8.
53. Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol 2012;5:7-18.
54. Rastrick J, Birrell M. The role of the inflammasome in fibrotic respiratory diseases. Minerva Med 2014;105:9-23.
55. Sauleda J, García-Palmer FJ, González G, Palou A, Agustí AG. The activity of cytochrome oxidase is increased in circulating lymphocytes of patients with chronic obstructive pulmonary disease, asthma, and chronic arthritis. Am J Respir Crit Care Med 2000;161:32-5.
56. Salmi M, Granfors K, MacDermott R, Jalkanen S. Aberrant binding of lamina propria lymphocytes to vascular endothelium in IBD. Gastroenterology 1994;106:596-605.
57. Maltby S, Wohlfarth C, Gold M, Zbytnuik L, Hughes MR, McNagny KM. CD34 is required for infiltration of eosinophils into the colon and pathology associated with DSS-induced ulcerative colitis. Am J Pathol 2010;177:1244-54.
58. Kinose D, Ogawa E, Hirota T, Ito I, Kudo M, Haruna A, et al. A NOD2 gene polymorphism is associated with the prevalence and severity of chronic obstructive pulmonary disease in a Japanese population. Respirology 2012;17:164-71.
59. Ekbom A, Brandt L, Granath F, Löfdahl CG, Egesten A. Increased risk of both ulcerative colitis and Crohn's in a population suffering from COPD. Lung 2008;186:167-72.
60. Storch I, Sachar D, Katz S. Pulmonary manifestations of IBD. Inflamm Bowel Dis 2003;9:104-15.
61. Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based case-control study of IBD risk factors. J Gastroenterol Hepatol 2010;25:325-33.
62. Egesten A, Brandt L, Olsson T, Granath F, Inghammar M, Löfdahl CG, et al. Increased prevalence of multiple sclerosis among COPD patients and their first-degree relatives: a population based study. Lung 2008;186:173-8.
63. Tulic MK, Piche T, Verhasselt V. Lung-gut cross-talk: evidence, mechanisms, and implications for the mucosal inflammatory diseases. Clin Exp Allergy 2016;46:519-28.
64. Al-Absi AI, Cooke CR, Wall BM, Sylvestre P, Ismail MK, Mya M. Patterns of injury in mycophenolate mofetil-related colitis. Transplant Proc 2010;42:3591-3.
65. Maruotti N, D'Onofrio F, Neve A, Santoro N, Corrado A, Cantatore FP. Anti-TNF-α and risk of infections: the experience in one center. Panminerva Med 2014;56:31-4.
66. Ardelean DS, Gonska T, Wires S, Cutz E, Griffiths A, Harvey E, et al. Severe Ulcerative Colitis after rituximab therapy. Pediatrics, 2010;126: e243-e246.
67. Ratuapli SK, Depetris G, Shepard B, Nguyen CC. Severe colitis caused by biologics: what an endoscopist needs to know. Minerva Gastroenterol Dietol 2014;60:287-90.
68. Actis GC, Lagget M, Pellicano R, Rosina F. Pancolitis during etanercept treatment of rheumatoid arthritis relapsing on the administration of further two TNF-alpha inhibitors. Int J Colorectal Dis 2012;27:547-8.
69. Toussirot É, Houvenagel É, Goëb V, Fouache D, Martin A, Le Dantec P, et al. Development of IBD during anti-TNF alpha therapy for inflammatory rheumatic disease. A nation-wide series. Joint Bone Spine 2012;79:457-63.
70. Hvas CL, Kelsen J, Agnholt J, Dige A, Christensen LA, Dahlerup JF. Discrete changes in circulating regulatory T-cells during infliximab treatment of Crohn's disease. Autoimmunity 2010;43:325-33.
71. Actis GC, Pellicano R, Rosina F. Ulcerative proctitis in out-patient practice: an unexpected clinical challenge. Minerva Gastroenterol Dietol 2014;60:201.
72. Melum E, Franke A, Karlsen TH. Genome-wide association studies: a summary for the clinical gastroenterologist. World J Gastroenterol 2009;15:5377-96.
73. Catanzaro R, Anzalone MG, Calabrese F, Milazzo M, Capuana ML, Italia A, et al. The gut microbiota and its correlations with the central nervous system disorders. Panminerva Med 2015;57:127-43.
74. Marks DJ. Defective immunity in inflammatory bowel disease: a Crohn's disease exclusivity? Curr Opin Gastroenterol 2011;27:328-34.
75. Actis GC, Rosina F, MacKay IR. Inflammatory bowel disease: beyond the boundaries of the bowel. Expt Rev Gastroenterol Hepatol 2011;5:401-10.
76. McGonagle D, Aziz A, Dickie LJ, McDermott MF. An Integrated Classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatric Res 2009;65:38R-45R.
77. Ko Y, Kariyawasam V, Karnib M, Butcher R, Samuel D, Alrubaie A, et al. IBD environmental risk factors. A population-based case control study of middle Eastern migration in Australia. Clin Gastroenterol Hepatol 2015;13:1453-63.